DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Rhinovirus Infection - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Rhinovirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhinovirus Infection and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Rhinovirus Infection Overview
- Therapeutics Development
- Pipeline Products for Rhinovirus Infection - Overview
- Pipeline Products for Rhinovirus Infection - Comparative Analysis
- Rhinovirus Infection - Therapeutics under Development by Companies
- Rhinovirus Infection - Therapeutics under Investigation by Universities/Institutes
- Rhinovirus Infection Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Rhinovirus Infection - Products under Development by Companies
- Rhinovirus Infection - Products under Investigation by Universities/Institutes
- Rhinovirus Infection - Companies Involved in Therapeutics Development
- AIMM Therapeutics B.V.
- Biological Mimetics, Inc.
- Biota Pharmaceuticals, Inc.
- Boehringer Ingelheim GmbH
- Johnson & Johnson
- Novartis AG
- Theraclone Sciences, Inc.
For more information visit http://www.researchandmarkets.com/research/sn2nwj/rhinovirus